ORIGINAL PAPER
Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer
1
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
2
Department of Clinic General Oncological and Endocrinological Surgery, Regional Hospital, Kielce, Poland
3
The Faculty of Mathematics and Natural Sciences, Jan Kochanowski University, Kielce, Poland
Submission date: 2020-02-24
Final revision date: 2020-02-29
Acceptance date: 2020-02-29
Publication date: 2020-03-31
Medical Studies 2020;36(1):6-13
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Increased concentrations of pentraxin 3 (PTX 3) were diagnosed in acute pancreatitis (AP) and in pancreatic ductal adenocarcinoma (PDAC).
Aim of the research:
To assess of the clinical usefulness of PTX3 in the early differentiation of AP from PDAC.
Material and methods:
The test group consisted of 125 patients with AP and 24 people with PDAC, as well as 52 healthy subjects. The following concentrations were tested in plasma: PTX3, C-reactive protein (CRP), interleukin-6 (IL-6), and CA-19.9.
Results:
The mean PTX3 concentration in the moderately-severe AP (MAP) or severe AP (SAP) equalled 16.53 ng/ml and was significantly higher in comparison with mild AP (9.60 ng/ml; p = 0.0007) and the control group (2.31 ng/ml). In the case of patients with PDAC, the mean concentration of PTX3 was 9.20 ng/ml and was significantly higher than in the control group (2.31 ng/ml); p < 0.0001. A significantly higher average CRP value of 100.37 mg/l and IL-6 91.65 pg/ml was also found in patients with PDAC compared to the control group (p < 0.0001). Tested pro-inflammatory cytokines were significantly higher in patients with MAP or SAP than in those with PDAC (p < 0.05). The ROC curve confirms the clear connection of PTX3 level and PDAC in comparison with the control group (p = 0.0001), relatively low sensitivity, and high specificity. However, the results were not significant enough to allow us to differentiate cancer from AP (p > 0.05).
Conclusions:
Pentraxin 3 can be a marker in the prediction of the severe course of AP, but its clinical usefulness for the differentiation of PDAC was not confirmed.
Increased concentrations of pentraxin 3 (PTX 3) were diagnosed in acute pancreatitis (AP) and in pancreatic ductal adenocarcinoma (PDAC).
Aim of the research:
To assess of the clinical usefulness of PTX3 in the early differentiation of AP from PDAC.
Material and methods:
The test group consisted of 125 patients with AP and 24 people with PDAC, as well as 52 healthy subjects. The following concentrations were tested in plasma: PTX3, C-reactive protein (CRP), interleukin-6 (IL-6), and CA-19.9.
Results:
The mean PTX3 concentration in the moderately-severe AP (MAP) or severe AP (SAP) equalled 16.53 ng/ml and was significantly higher in comparison with mild AP (9.60 ng/ml; p = 0.0007) and the control group (2.31 ng/ml). In the case of patients with PDAC, the mean concentration of PTX3 was 9.20 ng/ml and was significantly higher than in the control group (2.31 ng/ml); p < 0.0001. A significantly higher average CRP value of 100.37 mg/l and IL-6 91.65 pg/ml was also found in patients with PDAC compared to the control group (p < 0.0001). Tested pro-inflammatory cytokines were significantly higher in patients with MAP or SAP than in those with PDAC (p < 0.05). The ROC curve confirms the clear connection of PTX3 level and PDAC in comparison with the control group (p = 0.0001), relatively low sensitivity, and high specificity. However, the results were not significant enough to allow us to differentiate cancer from AP (p > 0.05).
Conclusions:
Pentraxin 3 can be a marker in the prediction of the severe course of AP, but its clinical usefulness for the differentiation of PDAC was not confirmed.
REFERENCES (25)
1.
Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res 2011; 343: 237-249.
2.
Casula M, Montecucco F, Bonaventura A, Liberale L, Vecchié A, Dallegri F, Carbone F. Update on the role of pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol 2017; 99: 1-12.
3.
Poznanski M, Brzezianska-Lasota E, Kiszalkiewicz J, Kurnatowska I, Kroczyńska-Bednarek J, Pękala-Wojciechowska A, Pietras T, Antczak A. Serum levels and gene expression of pentraxin 3 are elevated in COPD. Adv Med Sci 2018; 64: 85-89.
4.
Sharma A, Khan R, Gupta N, Sharma A, Zaheer MS, Abbas M, Khan SA. Acute phase reactant, pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis. Clin Chim Acta 2018; 480: 65-70.
5.
Lee HH, Kim SY, Na JC, Yoon YE, Han WK. Exogenous pentraxin-3 inhibits the reactive oxygen species-mitochondrial and apoptosis pathway in acute kidney injury. PLoS One 2018; 13: e0195758.
6.
Shiraki A, Kotooka N, Komoda H, Hirase T, Oyama JI, Node K. Pentraxin-3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep 2016; 5: 290-295.
7.
Hamed S, Behnes M, Pauly D, Lepiorz D, Barre M, Becher T, Lang S, Akin I, Borggrefe M, Bertsch T, Hoffmann U. Pentraxin-3 predicts short- and mid-term mortality in patients with sepsis and septic shock during intensive care treatment. Clin Lab 2018; 64: 999-1011.
8.
Lee YT, Gong M, Chau A, Wong WT, Bazoukis G, Wong SH, Lampropoulos K, Xia Y, Li G, Wong MCS, Liu T, Wu WKK, Tse G; International Heath Informatics Study (IHIS) Network. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: a systematic review and meta-analysis. J Infect 2018; 76: 1-10.
9.
Kusnierz-Cabala B, Gurda-Duda A, Dumnicka P, Panek J, Pawlica-Gosiewska D, Kulig J, Solnica B. Plasma pentraxin 3 concentrations in patients with acute pancreatitis. Clin Lab 2013; 59: 1003-1008.
10.
Meryk P, Dumnicka P, Kuśnierz-Cabala B, Kuźniewski M, Kapusta M, Gurda-Duda A, Goebels M, Pawlica-Gosiewska D, Kulig J. Diagnostic importance of pentraxins at the early phase of acute pancreatitis. Przegl Lek 2014; 71: 309-313.
11.
Zhang D, Ren WH, Gao Y, Wang NY, Wu WJ. Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer. Asian Pac J Cancer Prev 2013; 14: 4215-4221.
12.
Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 2011; 17: 2395-2399.
13.
Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, Tamura K, Okusaka T. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br J Cancer 2013; 109: 739-746.
14.
Rosendahl AH, Gundewar C, Said Hilmersson K, Ni L, Saleem MA, Andersson R. Conditionally immortalized human pancreatic stellate cell lines demonstrate enhanced proliferation and migration in response to IGF-I. Exp Cell Res 2015; 330: 300-310.
15.
Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C, Mantovani A. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 2015; 160: 700-714.
16.
Bonavita E, Mantovani A, Garlanda C. PTX3 acts as an extrinsic oncosuppressor. Oncotarget 2015; 6: 32309-32310.
17.
Zaheer A, Singh VK, Qureshi RO, Fishman EK. The revised Atlanta classification for acute pancreatitis: updates in imaging terminology and guidelines. Abdom Imaging 2013; 38: 125-136.
18.
Rosolowski M, Lipinski M, Dobosz M, Durlik M, Głuszek S, Kuśnierz K, Lampe P, Małecka-Panas E, Nowakowska-Duława E, Nowak-Niezgoda M, Radomańska B, Talar-Wojnarowska R, Wereszczyńska-Siemiątkowska U, Rydzewska G. Management of acute pancreatitis (AP) - Polish Pancreatic Club recommendations. Prz Gastroenterol 2016; 11: 65-72.
19.
Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437.
20.
Kirkegard J, Cronin-Fenton D, Heide-Jorgensen U, Mortensen FV. Acute pancreatitis and pancreatic cancer risk: a nationwide matched-cohort study in Denmark. Gastroenterology 2018; 154: 1729-1736.
21.
Simsek O, Kocael A, Kocael P, Orhan A, Cengiz M, Balcı H, Ulualp K, Uzun H. Inflammatory mediators in the diagnosis and treatment of acute pancreatitis: pentraxin-3, procalcitonin and myeloperoxidase. Arch Med Sci 2018; 14: 288-296.
22.
Watt J, Siddiqui I, Radon T, Dowe T, Crnogorac-Jurcevic T, Allavena O, Kocher H. Pentraxin 3 is a stromal biomarker in pancreatic ductal adenocarcinoma. Gastroenterology 2014; 146 Suppl 1: S276-S276.
23.
Ying TH, Lee CH, Chiou HL, Yang SF, Lin CL, Hung CH, Tsai JP, Hsieh YH. Knockdown of pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep 2016; 6: 29385.
24.
Deng LH, Hu C, Cai WH, Chen WW, Zhang XX, Shi N, Huang W, Ma Y, Jin T, Lin ZQ, Jiang K, Guo J, Yang XN, Xia Q. Plasma cytokines can help to identify the development of severe acute pancreatitis on admission. Medicine 2017; 96: e7312.
25.
Aksoy EK, Sapmaz FP, Doğan Ö, Göktaş Z, Uzman M, Nazlıgül Y. Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis. Gastroenterology Rev 2019; 14: 48-54.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
